Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Levodopa had a soft 2025, and Germany showed it most plainly, being the dearest market we follow. German material opened the year around USD 126,000/MT and gave ground almost every quarter, ending near USD 118,000/MT, a fall of roughly 6.3%. The reason was no mystery. Asian producers were turning out more than buyers wanted, and tariffs had knocked demand off its stride. The global average moved the same way, from USD 88,000/MT in Q1 to USD 83,000/MT by December. Things only shifted once 2026 began: inventories came back to normal, feedstock costs settled, and the global figure climbed back to USD 87,000/MT by the second quarter.
The molecule itself, Levodopa (C9H11NO4), is an aromatic amino acid that the body turns straight into dopamine, which is exactly why Parkinson's medicine leans on it so heavily. It shows up as a white to off-white crystalline powder. Makers get there two ways: multi-step synthesis off vanillin and related aromatics, or microbial fermentation. Parkinson's treatment swallows the bulk of demand, somewhere near three-quarters, and almost never on its own, since it travels with carbidopa or benserazide. What remains goes to combination generics, a few restless-legs products, and a slim nutraceutical corner. On price, the usual suspects apply: the cost of aromatic intermediates and chiral catalysts, energy, how much generic demand is out there, and whatever the trade file looks like for Chinese and Indian cargo that quarter.
For the back half of 2026, think steady, with a slight tilt upward. All that Chinese capacity built over two years means the market is well stocked, so what sets the price now is the cost of making Levodopa, not any shortage of it. Export inventories have thinned to healthier levels. Parkinson's demand keeps turning over at its usual pace. Add it up and you have a market that should drift rather than lurch.
The risks are easy to name. On the upside, dearer aromatic intermediates or catalysts, or another tariff round that scrambles trade flows, would pull tonnage out of the high-cost regions in a hurry. On the downside, a fresh wave of Chinese oversupply or a lull in generic buying would send spot values back toward where they bottomed last year.
| Region | 2026 Price Range (USD/MT) | Outlook |
| Global Average | 86,000 - 92,000 | Firmer generics demand, inventories back to normal |
| United States | 116,000 - 125,000 | Import exposure and regulation keep the US firm |
| China | 65,000 - 72,000 | Deep capacity anchors the global low |
| Germany | 120,000 - 130,000 | Energy and compliance keep Germany on top |
| India | 85,000 - 92,000 | Export economics hold a firm middle |
The US number came in at USD 118,000/MT for Q2, up from USD 114,000/MT the quarter before, so roughly 3.5% higher. Two things did the work. Generic formulators had run their shelves down and came back to buy, and the aromatic intermediates that feed the molecule cost a little more than they had.
Why did the price of Levodopa change in Q2 2026 in United States?
Most of this was timing. Q1 stocks were thin, so a return to buying was coming one way or another, and it duly arrived. Firmer intermediate costs pushed up the cost base at the same moment. And with the 2025 tariff drama mostly over, there was nothing to send the quarter any higher than USD 118,000/MT.
China stayed the cheapest place to buy anywhere, yet even here the number crept up, reaching USD 66,000/MT against USD 64,000/MT in Q1, a gain near 3.1%. Export orders were recovering, and the inputs to fermentation and synthesis had grown a touch pricier.
Why did the price of Levodopa change in Q2 2026 in China?
The pull came from overseas, formulators mostly, rebuilding stock and leaving less on the spot market to go around. Energy and intermediate costs edged the bottom higher. But China has capacity to spare, and that is what stopped the move at USD 66,000/MT.
Nobody paid more than Germany in Q2. At USD 122,000/MT, about 2.5% over the USD 119,000/MT of Q1, German prices carried two burdens at once: energy and compliance costs that will not budge, and a European formulation sector that had started buying again.
Why did the price of Levodopa change in Q2 2026 in Germany?
European buyers came off the sidelines as their stocks ran low. Energy and regulation kept German break-even well above everyone else's. Put together, the quarter landed at USD 122,000/MT.
India sat where it usually sits, in the middle, at USD 86,000/MT. That was around 2.4% above the USD 84,000/MT of Q1, with costlier imported intermediates and steady export orders from formulation houses doing the lifting.
Why did the price of Levodopa change in Q2 2026 in India?
Buying held up on both the export and domestic sides. Imported intermediates cost more, which raised the bottom. The two together put the quarter near USD 86,000/MT.
After a rough year, the US found its feet in Q1 at USD 114,000/MT, about 0.9% above Q4 2025. Buyers were cautious but restocking, and intermediate costs had stopped falling.
Why did the price of Levodopa change in Q1 2026 in United States?
Once the 2025 glut had cleared, purchases resumed, though selectively. Steadier feedstock gave the market a floor to stand on, and it settled at USD 114,000/MT.
China opened the year at USD 64,000/MT, up about 1.6% from Q4. Production came back after the holidays, and the first export enquiries firmed up a market that had scraped bottom late in 2025.
Why did the price of Levodopa change in Q1 2026 in China?
Two things steadied offers: leftover 2025 stock finally clearing, and a modest pickup in export interest. With capacity deep as ever, prices held near USD 64,000/MT.
Germany printed USD 119,000/MT in Q1, roughly 0.8% over Q4. High energy costs and a gradual European restock kept the market firm at the top end.
Why did the price of Levodopa change in Q1 2026 in Germany?
Energy-linked costs kept break-even high while European buyers topped up slowly. The quarter came in near USD 119,000/MT.
India began at USD 84,000/MT, about 1.2% above Q4, as import costs steadied and formulation demand carried on.
Why did the price of Levodopa change in Q1 2026 in India?
Steady offtake met levelling intermediate costs, and prices firmed to USD 84,000/MT after a weak 2025.
Levodopa spent 2025 on the back foot, then bottomed and turned up as 2026 came in. The average went from USD 84,000/MT in Q2 2025 down to USD 82,000/MT in Q3, steadied at USD 83,000/MT in Q4, then rose to USD 85,000/MT in Q1 2026 and USD 87,000/MT in Q2, a net gain of about 3.6%. Asian oversupply and tariff-hit demand pulled it down; normalising stocks and firmer inputs pulled it back.
| Quarter | Price (USD/MT) | QoQ Change | Direction |
| Q2 2026 | 87,000 | +2.4% | ↑ Rising |
| Q1 2026 | 85,000 | +2.4% | ↑ Rising |
| Q4 2025 | 83,000 | +1.2% | ↑ Rising |
| Q3 2025 | 82,000 | -2.4% | ↓ Falling |
| Q2 2025 | 84,000 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Levodopa fell for most of 2025 and only steadied near the end. The average opened around USD 88,000/MT and closed near USD 83,000/MT, off about 5.7%. Two straight quarters of Asian oversupply, a weak spell in Chinese manufacturing, and tariff-driven disruption to US and export demand set the tone. The floor did not form until Q4, once inventories had cleared.
The US drifted from about USD 122,000/MT in early 2025 to USD 113,000/MT by Q4, a decline near 7.4%. The first half did most of the damage: buyers had stocked up heavily ahead of expected tariffs, then sat on their hands, so inventory piled up. Prices found a floor late in the year. If one factor stood out, it was the uncertainty hanging over Chinese and Indian shipments.
China took the hardest hit, sliding from roughly USD 69,000/MT to USD 63,000/MT, down about 8.7%. Output resumed after the holidays into weak overseas interest, and with domestic manufacturing contracting on top of that, exporters cut offers just to move product. Oversupply meeting tariff-hit demand was the whole story.
Germany came off from around USD 126,000/MT to USD 118,000/MT, roughly 6.3% lower. Softer European buying and the constant pull of cheaper Asian material weighed on prices, but steep energy costs kept the slide shallow. The tension all year was import competition against an expensive home cost base.
India eased from about USD 90,000/MT to USD 83,000/MT, down 7.8%. Weak export demand and plenty of regional supply pressed on prices throughout, with imported intermediate costs lending only partial support. Soft demand abroad did most of it.
Expert Market Research: Your Source for Real-Time Levodopa Price Intelligence
Expert Market Research watches Levodopa prices without a break, in every region that matters on the map, whether it is producing or consuming. We chase the why behind the number, not just the number: what aromatic intermediates and chiral catalysts are doing, how fermentation and synthesis costs are moving, where generic Parkinson's demand is heading, and how trade policy keeps rerouting Asian cargo. The forecasts pull together feedstock economics, trade-flow data, capacity use, and a read on geopolitical risk across the board. Get in touch with Expert Market Research for Levodopa pricing, analysis built around your questions, and help thinking through procurement.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Parkinson's treatment takes almost three-quarters of it, with levodopa paired to carbidopa or benserazide. The rest is split among combination generics, restless-legs products, and a small nutraceutical slice.
For Q2 2026, the average ran USD 118,000/MT in the US, USD 66,000/MT in China, USD 122,000/MT in Germany, and USD 86,000/MT in India. Germany is the most expensive, weighed down by energy and regulatory costs.
It fell. The global average dropped from roughly USD 88,000/MT early in 2025 to USD 83,000/MT by Q4, about 5.7%, on Asian oversupply, a soft patch in Chinese manufacturing, and tariff-driven demand disruption.
Mostly three things. China had built too much capacity and oversupplied the market, its manufacturing sector was contracting, and trade-policy uncertainty kept US and export demand off balance.
Somewhere in the USD 86,000 to 92,000/MT band for the rest of 2026, held up by normalised inventories, steady generic demand, and calmer feedstock costs.
Germany leads on price, thanks to energy and compliance, with the US close behind on import and regulatory costs. India holds the middle on export economics, and China stays cheapest on sheer capacity.
Every month. For live pricing, reach the Expert Market Research team directly.
Chiefly the cost of aromatic intermediates and catalysts, energy, and how much generic demand is around. Tariffs, export licences, and freight on the Asian routes can jolt things short term.
China makes the most, India comes next, and Singapore adds a little. When Chinese capacity or costs move, the rest of the world usually feels it inside a quarter or two.
Line contracts up with Asian production and inventory swings, weigh a fixed price against index-linked supply, and get cover in place before demand firms. The first hint of where the global floor is going tends to show up in Chinese export offers.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.